Peter Hudson
Peter is a genetic engineer who has designed and developed therapeutic antibodies for clinical oncology. He is CSO of Avipep and formerly Director of the Vic Cancer Biologics consortium (led by Avipep 2013-2017). Peter currently advises Cartherics for CarT designs and Isoclide Medical for RIT therapy.
Abstracts this author is presenting: